

29 October 2010

Instem Life Science Systems plc
("Instem" or the "Company")

VOTING RIGHTS AND CAPITAL

In conformity with the Disclosure and Transparency Rules we would like to notify the market of the following:

The Company's issued share capital consists of 11,714,286 ordinary shares with a nominal value of 10p each ('Ordinary Shares'). The Company does not hold any Ordinary Shares in Treasury.

Therefore, the total number of voting rights in the Company is 11,714,286

The figure of 11,714,286 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

For further information, please contact:

Instem Life Science Systems plc Phil Reason, CEO	+44 (0) 1785 825600
Brewin Dolphin - Financial Advisor, Broker & NOMAD Mark Brady Sean Wyndham-Quin	+44 (0) 0845 213 4730
Rickitt Mitchell - Joint Financial Advisor to the Company Matthew Bryden-Smith Neil Mitchell	+44 (0) 161 834 0600
Threadneedle Communications Caroline Evans-Jones Fiona Conroy Josh Royston	+44 (0) 20 7653 9850

About Instem Life Science Systems plc

Instem (AIM:INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

Instem has over 80 customers in North America, Europe, China, India and Japan, including seven of the top ten pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 100 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor location in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.

To learn more about Instem please visit the Company's website, www.instem-lss.com, or its investor centre <http://investors.instem-lss.com/>.